

Auricular Chromoblastomycosis: A Case Report and Review of Published Literature

Katlein França · Ricardo Tadeu Villa · Viviane Reis de Azevedo Bastos · Ana Carolina C. Almeida · Katyane Massucatti · Daniella Fukumaru · Valcinir Bedin

Received: 10 September 2010 / Accepted: 1 February 2011 / Published online: 17 February 2011
© Springer Science+Business Media B.V. 2011

Abstract Subcutaneous chromoblastomycosis is an infection commonly seen in tropical and subtropical climates, usually caused by trauma with vegetables and often affects the host's lower limbs. We report a case of auricular chromoblastomycosis in a 67-year-old man and discuss the rarity of this clinical manifestation of chromoblastomycosis in the medical literature. In the present case, the etiologic agent was *Fonsecaea pedrosoi*, the most common agent found in Brazil.

Keywords Chromoblastomycosis · Dematiaceous fungi · Auricular lesion

Introduction

Chromoblastomycosis is a chronic fungal infection of the skin and the subcutaneous tissue caused by traumatic inoculation of a specific group of dematiaceous fungi such as *Fonsecaea pedrosoi*, *Cladophialophora carrionii*, *Phialophora verrucosa*, *Fonsecaea compacta*, *Rhinocladiella aquaspersa*, or *Exophiala dermatitidis* through the skin [1]. It is characterized by the development of warty lesions, usually on the foot and leg. The lesions develop over a period of years and usually remain localized; metastases are very rare. The agents often gain entry into the human body by contact with thorns or wood splinters.

The objective of this article is to present a case of auricular chromoblastomycosis caused by *Fonsecaea pedrosoi* in a 67-year-old man and discuss the clinical and therapeutic aspects of this rare manifestation of chromoblastomycosis in the literature.

Case Report

A 67-year-old man presented to consultation referring pruriginous papules on the left auricular surface. He

K. França · A. C. C. Almeida · K. Massucatti · D. Fukumaru
Especializada em Dermatologia da Fundação Técnico Educacional Souza Marques—Pele Saudável, São Paulo, Brazil

R. T. Villa · V. R. de Azevedo Bastos (✉)
Professor de Especialização em Dermatologia da Fundação Técnico Educacional Souza Marques—Pele Saudável—Rua São Domingos, 69, Bela Vista—CEP, São Paulo 01326-000, Brazil
e-mail: vivianerazevedo@terra.com.br

V. R. de Azevedo Bastos
Disciplina de Infectologia da Universidade Federal de São Paulo, São Paulo, Brazil

V. Bedin
Coordenador do Curso de Especialização em Dermatologia da Fundação Técnico Educacional Souza Marques—Pele Saudável, São Paulo, Brazil

used to work in rural zone, since his 8 years old. These lesions appeared 3 years earlier this appointment, and the patient had seen another dermatologist at that time. He stated that a biopsy was performed and it was inconclusive. He was treated with topical corticosteroids, but he had a lower response.

Physical examination revealed an erythematous plaque with 30×17 mm and few nodules on this auricular surface (Fig. 1). The patient complained of intermittent pruritus and local sting (Fig. 2).

A new biopsy and a fungal culture were performed, and the material was sent to the Mycological Laboratory of “Fundação Pele Saudável”. The material was cultured on Sabouraud Dextrose Ágar (SDA) with chloramphenicol and Potato Dextrose



Fig. 1 Erythematous plaque with 30×17 mm and few nodules on auricular surface




Fig. 2 Biopsy showing pseudo-epitheliomatous hyperplasia of the epidermis, dense infiltration of macrophages constituting granulomas, lymphocytes, eosinophils, and neutrophils in dermis. Levedures with a brown pigment inside of the macrophages and giant cells

Ágar (PDA), and after about 10 days, grayish cottony fungal colonies grew out in both media. The bacterial and mycobacterial cultures are negative. PDA, Malt Extract Ágar (MEA), and Oatmeal Ágar (OA) were used to perform microscopic examination.

Abundant septate, dark brown hyphae, and suberect conidiophores that highly branch at apices were observed. The conidiophores were pale brown, erect, septate, and sympodial with conidiogenous zones confined to the upper portion. The conidia were brown and barrel shaped, arranged in short chain, characteristic of *Fonsecaea pedrosoi*, proving the diagnosis of chromoblastomycosis (Fig. 3). Although there is no standard method for in vitro susceptibility testing with *Fonsecaea pedrosoi*, we also performed a susceptibility antifungal test against itraconazole, voriconazole, posaconazole, and amphotericin B.

The susceptibility test procedures were performed according to the Clinical and Laboratory Standard Institute (CLSI) document M38-A2 published in 2008. The MIC value observed was $1,0 \mu\text{g/ml}$ for all the drugs.

The patient was treated with itraconazole 200 mg/day for 10 months and eight sessions of cryotherapy. The patient referred an improvement in symptoms. A clinical remission of nodular lesions was observed. (Fig. 4). The treatment at this clinical location has low response when compared to other areas. The case reported marks improvement but not complete clinical and mycological cure.

Discussion

Chromoblastomycosis is most frequently observed in tropical zones, occurring generally in people engaged in forest or bush clearance. In subtropical regions, it can be observed in rural workers, especially those who do not routinely wear shoes, leading commonly to lower limb involvement [2].

In tropical humid regions, *Fonsecaea pedrosoi* is the principal etiologic agent encountered in chromoblastomycosis but in semiarid climate areas are observed several cases caused by *Cladophialophora carrionii* [3]. Less frequently, the disease is caused by *Phialophora verrucosa*, *Rhinocladiella aquaspersa*, or *Exophiala dermatitidis*. Recently *Exophiala jeanselmei* and *Exophiala spinifera* have also been observed forming muriform cells in lesions of




Fig. 3 Fungal culture isolating *Fonsecaea pedrosoi*



Fig. 4 Patient after 10 months of treatment with itraconazole and 8 sessions of cryotherapy

chromoblastomycosis. *Fonsecaea compacta* is an uncommon agent [4].

Chromoblastomycosis should be differentiated from mycetoma, blastomycosis, leishmaniasis, tuberculosis, leprosy, and tertiary syphilis. However, the clinical and microscopic findings are diagnostic [5].

In this patient, the Montenegro's reaction was negative and the amastigote form of leishmania was not visualized, which differentiates from auricular leishmaniasis.

The treatment has been difficult, and a combination of various treatment modalities is sometimes needed to achieve the best result. There are three treatment modalities: physical, chemotherapy, and combination therapy. Their success is related to the causative agent, the clinical form, and also the severity of the lesions [6]. Surgical excision can be done but it requires the removal of a margin of uninfected tissue to prevent local dissemination. Criosurgery with liquid nitrogen is a low-cost, safe, and efficient method [7–10].

Most of the patients can be treated with itraconazole, terbinafine, or a combination of both. Itraconazole showed an excellent profile in the therapy of chromoblastomycosis. It is clinically and laboratory safe, even when used at high doses and during a long period of time [11, 12]. There is no treatment of choice for this neglected mycosis. In general, it should be guided according to clinical, mycological, and histopathological criteria [6].

Auricular chromoblastomycosis constitutes a rarity in several cases already published. Our MEDLINE search revealed only four cases, all occurred in elderly men [13–16]. In all cases, the lesion was not suggestive and the diagnosis was casual. *Fonsecaea* spp., the most frequent agent isolated, was observed in two cases, and in the other cases, agents involved were *Rhinocladiella aquaspersa* and *Phialophora verrucosa* (Table 1). With the exception of the case published in Japan, we found the lack of information regarding the antifungal drugs used to treat these forms of chromoblastomycosis and also did not

Table 1 Summary of 04 cases of auricular chromoblastomycosis already published

| Origin | Genera M/F ^a | Age | Isolated Agent | Duration in years | Treatment (drug/dosage) | Outcome | Reference |
|----------|-------------------------|-----|----------------------------------|-------------------|----------------------------|--|-----------|
| Colombia | M | 60 | <i>Rhinocladiella aquaspersa</i> | 5 | — ^b | — ^b | [13] |
| Brazil | M | 66 | <i>Phialophora verrucosa</i> | 3 | — ^b | Improvement of the lesion, but no cure | [14] |
| Cuba | M | 45 | <i>Fonsecaea pedrosoi</i> | 15 | — ^b | — ^b | [15] |
| Japan | M | 71 | <i>Fonsecaea pedrosoi</i> | 0,3 | Oral Flucytosine/7.5 g/day | Complete resolution | [16] |

^a M: Male/F:Female

^b data not mentioned

obtain information about the success or failure of treatment of these cases.

In summary, our report addresses the clinical aspects of a rare clinical manifestation of chromoblastomycosis.

References

1. Rubin HA, Bruce S, Rosen T, McBride ME. Evidence for percutaneous inoculation as the mode of transmission for chromoblastomycosis. *J Am Acad Dermatol.* 1991;25(5 Pt 2):951–4.
2. Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: novel perspectives. *Curr Opin Infect Dis.* 2006;19:148–52.
3. Santos Andrd LS, Palmeira Vanila F, Sonia Rozental, Knipp Lucimar F, Leonardo Nimrichter, Alviano Daniela S, Rodruigues Marcio L, Alviano Celuta S. Biology and pathogenesis of *Fonsecaea pedrosoi*, the major etiologic agent of chromoblastomycosis. *FEMS Microbiol Rev.* 2007;31:570–91.
4. Queiroz-Telles F, McGinnis MR, Salkin I, Graybill JR. Subcutaneous mycoses. *Infect Dis Clin North Am.* 2003;17:59–85.
5. Carrion AL. Chromoblastomycosis and related infections: new concepts, differential diagnosis, and nomenclatorial implications. *Int J Dermatol.* 1975;14:27–32.
6. Queiroz-Telles FA, Esterre P, Perez-Blanco M, Vitale RG, Guedes Salgado C, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. *Medical Mycology.* 2009;47:3–15.
7. Bonifaz A, Martinez-Soto E, Carrasco-Gerard E, Peniche J. Treatment of chromoblastomycosis with itraconazole, cryosurgery, and a combination of both. *Int J Dermatol.* 1997;36:542–7.
8. Pimentel ERA, Castro LGM, Cué LC, Sampaio SAP. Treatment of chromomycosis by cryosurgery with liquid nitrogen. *J Dermatol Surg Oncol.* 1989;15:72–7.
9. Sittart JAS, Valente NYS. Tratamento da cromomicose pelo nitrogênio líquido. *Med Cut ILA.* 1986;14:227–32.
10. Graham GF, Torre D. New indications for cryosurgery in infected patients. In: Roenigk RK, Roenigk HH, editors. *Surgical dermatology, Advances in current practice.* St. Louis: Mosby; 1993. p. 61–9.
11. Kullavanijaya P, Rojanavanich V. Successful treatment of Chromoblastomycosis due to *Fonsecaea pedrosoi* by the combination of itraconazole and cryotherapy. *Int J Dermatol.* 1995;34(11):804–7.
12. Queiroz-Telles Filho F. A Cromoblastomicose no Estado do Paraná: etiologia, epidemiologia, clínica e terapêutica com itraconazol. *Rev Soc Bras Med Trop.* 1997;30(4):345–6.
13. Arango M, Jaramillo C, Cortés A, Restrepo A. Auricular chromoblastomycosis caused by *Rhinocladiella aquaspersa*. *Med Mycol.* 1998;36(1):43–5.
14. Bittencourt AL, Londero AT, Andrade JA. Auricular chromoblastomycosis. A case report. *Rev Inst Med Trop Sao Paulo.* 1994;36(4):381–3.
15. Moya Duque S, Simón RD, Grillo Martínez R, Falcón Lincheta L. Chromomycosis with unusual location. Presentation of 2 cases. *Rev Cubana Med Trop.* 1989;41(1):93–101.
16. Iwatsu T, Takano M, Okamoto S. Auricular chromomycosis. *Arch Dermatol.* 1983;119(1):88–9.